Prof. Bob Langer and Prof. Giovanni Traverso have co-founded Syntis Bio, a biotech company that will use technology to “coat the stomach and potentially other organ surfaces, [change] the way that drugs are absorbed or, in the case of obesity, which hormones are triggered,” reports Allison DeAngelis for STAT.
Prof. Regina Barzilay joins The Economist’s “Babbage” podcast to discuss how artificial intelligence could enable health care providers to understand and treat diseases in new ways. Host Alok Jha notes that Barzilay is determined to “overcome those challenges that are standing in the way of getting AI models to become useful in health care.” Barzilay explains: “I think we really need to change our mindset and think how we can solve the many problems for which human experts were unable to find a way forward.”
Forbes selects innovators for the list’s Healthcare & Science category, written by senior contributor Yue Wang. On the list is MIT PhD candidate Yuzhe Yang, who studies AI and machine learning technologies capability to monitor and diagnose illnesses such as Parkinson's disease.
In an article for Fast Company, Lecturer Guadalupe Hayes-Mota offers five takeaways concerning the potential impact of AI on healthcare. Understanding AI’s healthcare potential “is crucial for business leaders and policymakers to foster an environment where AI and other analytics tools enhance rather than complicate societal outcomes,” Hayes-Mota writes.
ShareAmerica reporter Lauren Monsen spotlights Prof. Dina Katabi for her work in advancing medicine with artificial intelligence. “Katabi develops AI tools to monitor patients’ breathing patterns, hear rate, sleep quality, and movements,” writes Monsen. “This data informs treatment for patients with diseases such as Parkinson’s, Alzheimer’s, Crohn’s, and ALS (amyotrophic lateral sclerosis), as well as Rett syndrome, a rare neurological disorder.”
Writing for Forbes, Senior Lecturer Guadalupe Hayes-Mota '08, SM '16, MBA '16 explains how transformative strategies in global healthcare are “reshaping the pharmaceutical market dynamics.” This new method “transcends traditional financial tactics representing a fundamental shift in global health practices towards sustainable and universal access to essential medicines,” writes Hayes-Mota.
Prof. Amy Finkelstein speaks with New York Times reporter Sarah Kliff about “the impact of medical debt relief on individuals.” “The idea that maybe we could get rid of medical debt, and it wouldn’t cost that much money but it would make a big difference, was appealing,” says Finkelstein. “What we learned, unfortunately, is that it doesn’t look like it has much of an impact.”
Prof. Joseph Doyle and his colleagues are studying whether type 2 diabetes could be treated or improved by nutrition, reports Donna Eastlake for Food Navigator.
MIT researchers have found that “when an AI tool for radiologists produced a wrong answer, doctors were more likely to come to the wrong conclusion in their diagnoses,” report Daniel Payne, Carmen Paun, Ruth Reader and Erin Schumaker for Politico. “The study explored the findings of 140 radiologists using AI to make diagnoses based on chest X-rays,” they write. “How AI affected care wasn’t dependent on the doctors’ levels of experience, specialty or performance. And lower-performing radiologists didn’t benefit more from AI assistance than their peers.”
Writing for Fast Company, Senior Lecturer Guadalupe Hayes-Mota '08, SM '16, MBA '16 shares methods to address the influence of AI in healthcare. “Despite these advances [of AI in healthcare], the full spectrum of AI’s potential remains largely untapped,” explains Hayes-Mota. “Systemic hurdles such as data privacy concerns, the absence of standardized data protocols, regulatory complexities, and ethical dilemmas are compounded by an inherent resistance to change within the healthcare profession. These barriers underscore the urgent need for transformative action from all stakeholders to fully harness AI’s capabilities.”
MIT Innovation Fellow Brian Deese speaks with CNBC about how the new class of weight loss drugs will impact American taxes and the federal deficit. “These drugs could touch tens of millions of Americans, that’s the good news,” says Deese. “They have the potential to reduce obesity, address diabetes and reduce the health care costs associated with that. The problem is that the scale and the cost of these drugs is so large, that it could add enormously to the federal budget.”
Wardah Inam SM '12, PhD '16 founded Overjet, an AI platform that helps dentists “diagnose diseases from scans and other data,” reports Saritha Rai for Bloomberg. “Dentistry was more art than science, and I wanted to bring technology and AI to help dentists make objective decisions,” says Inam. “We began building and then improving our AI systems with tens of millions of pieces of data, including X-rays, historical information, dentist notes, and periodontal charts.”
Prof. Jonathan Gruber, MIT Innovation Fellow Brian Deese and Stanford doctoral student Ryan Cummings write for The New York Times about the health benefits of new weight-loss drugs and the risk they pose to American taxpayers. “The magnitude of potential benefit and potential cost — roughly $15,000 per year per person — posed by these drugs suggests that policymakers may have no alternative but to step in and bring their costs in line with their social benefits,” they write. “If policymakers succeed in doing so, we could build a model for drug price negotiation that enables an extraordinary medical breakthrough to improve both our health and our fiscal position.”
BioBot - a public health research, data and analytics firm co-founded by Mariana Matus PhD '18 and Newsha Ghaeli PhD '17 - is using wastewater testing to provide insights into growing infection rates and diseases across the country, reports Soledad O’Brien for WCVB-TV.
Research scientist Beth Pollack speaks with the New York Times’ Pam Belluck about her work studying the mechanisms of long Covid-19 and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). “Experts said the study, which is the N.I.H’s first detailed look at ME/CFS, should be considered only one step in understanding the condition, its severity and potential remedies,” explains Belluck. “We must advance the field towards research on treatment,” says Pollack.